medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2013, Number 3

<< Back Next >>

Salud Mental 2013; 36 (3)

Endophenotypes and biomarkers: an approach to molecular genetic studies of mental disorders

Díaz-Anzaldúa A, Velázquez-Pérez J, Nani VA, Berlanga C

Language: English
References: 55
Page: 181-188
PDF size: 108.91 Kb.


ABSTRACT

Many precise aspects of the etiology and pathophysiology of mental disorders are still unknown. Susceptibility to these disorders depends in part on variability in the genome sequence among individuals. The genotype, a given environment, a specific epigenetic profile and stochastic factors affect the phenotype, which includes body structures, physiological processes, and behavior. Since the access to the Central Nervous System is generally difficult and in most cases there are still no biological tests that necessarily contribute to diagnosis, psychiatric phenotypes are usually limited to clinical symptoms and functioning. Therefore, researchers are currently seeking alternatives to facilitate the identification of genetic risk factors. One strategy is to identify measurable biological, cognitive, and behavioral markers, intermediate phenotypes, or endophenotypes, which in the best case may be simpler than general psychiatric diagnoses, ideally with a precise biological meaning and a more direct relationship with the action of specific genes. Endophenotypes have been very useful in other fields of medicine. Currently, there are several proposed criteria and specifications for endophenotypes. Examples of possible types of endophenotypes or biomarkers, as well as treatment response phenotypes in some psychiatric disorders will be discussed in this review.


REFERENCES

  1. Flicek P, Ahmed I, Amode MR et al. Ensembl 2013. Nucleic Acids Res 2012.

  2. O’Huallachain M, Karczewski KJ, Weissman SM et al. Extensive genetic variation in somatic human tissues. Proc Natl Acad Sci U S A 2012;109:18018-18023.

  3. Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry 2011;168:1041-1049.

  4. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389.

  5. Kas MJ, Fernandes C, Schalkwyk LC, Collier DA. Genetics of behavioural domains across the neuropsychiatric spectrum; of mice and men. Mol Psychiatry 2007;12:324-330.

  6. Gottesman, II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645.

  7. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.

  8. Fabritz L, Damke D, Emmerich M et al. Autonomic modulation and antiarrhythmic therapy in a model of long QT syndrome type 3. Cardiovasc Res 2010;87:60-72.

  9. Gottesman II, Shields J. Genetic theorizing and schizophrenia. Br J Psychiatry 1973;122:15-30.

  10. Hasler G. Evaluating endophenotypes for psychiatric disorders. Rev Bras Psiquiatr 2006;28:91-92.

  11. Preston GA, Weinberger DR. Intermediate phenotypes in schizophrenia: a selective review. Dialogues Clin Neurosci 2005;7:165-179.

  12. Cannon TD, Keller MC. Endophenotypes in the genetic analyses of mental disorders. Annu Rev Clin Psychol 2006;2:267-290.

  13. Kendler KS, Neale MC. Endophenotype: a conceptual analysis. Mol Psychiatry 2010;15:789-797.

  14. Bellivier F, Henry C, Szoke A et al. Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression. Neurosci Lett 1998;255:143-146.

  15. Hauser J, Leszczynska A, Samochowiec J et al. Association analysis of the insertion/deletion polymorphism in serotonin transporter gene in patients with affective disorder. Eur Psychiatry 2003;18:129-132.

  16. Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 2004;14:121-129.

  17. Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neuropsychiatr Genet 2005;133B:110-115.

  18. Smeraldi E, Zanardi R, Benedetti F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-511.

  19. Arranz MJ, Bolonna AA, Munro J et al. The serotonin transporter and clozapine response. Mol Psychiatry 2000;5:124-125.

  20. Zanardi R, Benedetti F, Di Bella D et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000;20:105-107.

  21. Gonda X, Juhasz G, Laszik A et al. Subthreshold depression is linked to the functional polymorphism of the 5HT transporter gene. J Affect Disord 2005;87:291-297.

  22. Moncrieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331:155-157.

  23. Quintin P, Benkelfat C, Launay JM et al. Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder. Biol Psychiatry 2001;50:184-190.

  24. Hasler G, Drevets WC, Gould TD et al. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry 2006;60:93-105.

  25. Sobczak S, Honig A, Schmitt JA, Riedel WJ. Pronounced cognitive deficits following an intravenous L-tryptophan challenge in first-degree relatives of bipolar patients compared to healthy controls. Neuropsychopharmacology 2003;28:711-719.

  26. Pacchierotti C, Iapichino S, Bossini L et al. Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol 2001;22:18-32.

  27. Hallam KT, Olver JS, Chambers V et al. The heritability of melatonin secretion and sensitivity to bright nocturnal light in twins. Psychoneuroendocrinology 2006;31:867-875.

  28. Serretti A, Benedetti F, Mandelli L et al. Genetic dissection of psychopathological symptoms: insomnia in mood disorders and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 2003;121B:35-38.

  29. Lok A, Mocking RJ, Ruhe HG et al. Longitudinal hypothalamic-pituitary- adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 2012;37:892-902.

  30. Radley JJ, Kabbaj M, Jacobson L et al. Stress risk factors and stressrelated pathology: neuroplasticity, epigenetics and endophenotypes. Stress 2011;14:481-497.

  31. Mann JJ, Arango VA, Avenevoli S et al. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 2009;65:556-563.

  32. van Venrooij JA, Fluitman SB, Lijmer JG et al. Impaired neuroendocrine and immune response to acute stress in medication-naive patients with a first episode of psychosis. Schizophr Bull 2012;38:272-279.

  33. Chen AC, Manz N, Tang Y et al. Single-nucleotide polymorphisms in corticotropin releasing hormone receptor 1 gene (CRHR1) are associated with quantitative trait of event-related potential and alcohol dependence. Alcohol Clin Exp Res 2010;34:988-996.

  34. Page DT. A candidate circuit approach to investigating autism. Anat Rec (Hoboken) 2011;294:1671-1684.

  35. Jiang B, Kenna HA, Rasgon NL. Genetic overlap between polycystic ovary syndrome and bipolar disorder: the endophenotype hypothesis. Med Hypotheses 2009;73:996-1004.

  36. Lawrie SM, Whalley HC, Abukmeil SS et al. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk of developing schizophrenia. Biol Psychiatry 2001;49:811-823.

  37. Owens SF, Picchioni MM, Ettinger U et al. Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia. Brain 2012;135:2231-2244.

  38. Chakravarty MM, Felsky D, Tampakeras M et al. DISC1 and Striatal Volume: A Potential Risk Phenotype For mental Illness. Front Psychiatry 2012;3:57.

  39. Adler CM, Holland SK, Schmithorst V et al. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord 2004;6:197-203.

  40. Caligiuri MP, Brown GG, Meloy MJ et al. A functional magnetic resonance imaging study of cortical asymmetry in bipolar disorder. Bipolar Disord 2004;6:183-196.

  41. Ruocco AC, Amirthavasagam S, Zakzanis KK. Amygdala and hippocampal volume reductions as candidate endophenotypes for borderline personality disorder: a meta-analysis of magnetic resonance imaging studies. Psychiatry Res 2012;201:245-252.

  42. Sobczak S, Riedel WJ, Booij I et al. Cognition following acute tryptophan depletion: difference between first-degree relatives of bipolar disorder patients and matched healthy control volunteers. Psychol Med 2002;32:503-515.

  43. Robinson LJ, Thompson JM, Gallagher P et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 2006;93:105-115.

  44. Murphy FC, Sahakian BJ, Rubinsztein JS et al. Emotional bias and inhibitory control processes in mania and depression. Psychol Med 1999;29:1307-1321.

  45. Smith DJ, Muir WJ, Blackwood DH. Neurocognitive impairment in euthymic young adults with bipolar spectrum disorder and recurrent major depressive disorder. Bipolar Disord 2006;8:40-46.

  46. Ferrier IN, Chowdhury R, Thompson JM et al. Neurocognitive function in unaffected first-degree relatives of patients with bipolar disorder: a preliminary report. Bipolar Disord 2004;6:319-322.

  47. Olley AL, Malhi GS, Bachelor J et al. Executive functioning and theory of mind in euthymic bipolar disorder. Bipolar Disord 2005;7(Suppl 5):43-52.

  48. Nuechterlein KH, Subotnik KL, Ventura J et al. The puzzle of schizophrenia: tracking the core role of cognitive deficits. Dev Psychopathol 2012;24:529-536.

  49. Agnew-Blais J, Seidman LJ. Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: A quantitative and qualitative review. Cogn Neuropsychiatry 2012:1-39. En prensa. DOI:1 0.1080/13546805.2012.676309.

  50. Greenwood TA, Light GA, Swerdlow NR et al. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One 2012;7:e29630.

  51. Rajender G, Bhatia MS, Kanwal K et al. Study of neurocognitive endophenotypes in drug-naive obsessive-compulsive disorder patients, their first-degree relatives and healthy controls. Acta Psychiatr Scand 2011;124:152-161.

  52. Ersche KD, Turton AJ, Chamberlain SR et al. Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry 2012;169:926-936.

  53. Braff DL, Greenwood TA, Swerdlow NR et al. Advances in endophenotyping schizophrenia. World Psychiatry 2008;7:11-18.

  54. Zanger UM, Fischer J, Raimundo S et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001;11:573-585.

  55. Dorado P, Penas-Lledo EM, Llerena A. CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 2007;8:1597-1608.




2020     |     www.medigraphic.com